These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32374570)

  • 1. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis.
    Moiola L; Rommer PS; Zettl UK
    Curr Opin Neurol; 2020 Jun; 33(3):286-294. PubMed ID: 32374570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
    Schweitzer F; Laurent S; Fink GR; Barnett MH; Reddel S; Hartung HP; Warnke C
    Curr Opin Neurol; 2019 Jun; 32(3):305-312. PubMed ID: 30985373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New aspects of immunotherapy in multiple sclerosis].
    Pape K; Zipp F; Bittner S
    Nervenarzt; 2018 Dec; 89(12):1365-1370. PubMed ID: 29881971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Natalizumab can induce progressive multifocal leucoencephalopathy].
    Theódórsdóttir A; Blaabjerg M; Falah M
    Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
    Zhang Y; Wright C; Flores A
    J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
    Heesen C; Kleiter I; Nguyen F; Schäffler N; Kasper J; Köpke S; Gaissmaier W
    Mult Scler; 2010 Dec; 16(12):1507-12. PubMed ID: 20826527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
    Dubey D; Cano CA; Stüve O
    Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.
    De Giglio L; Grimaldi AE; Fubelli F; Marinelli F; Pozzilli C
    Expert Rev Neurother; 2019 May; 19(5):417-429. PubMed ID: 31094239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
    Major EO; Yousry TA; Clifford DB
    Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Risks with Immune Therapies in Multiple Sclerosis.
    Förster M; Küry P; Aktas O; Warnke C; Havla J; Hohlfeld R; Mares J; Hartung HP; Kremer D
    Drug Saf; 2019 May; 42(5):633-647. PubMed ID: 30607830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Mowry EM; McArthur JC
    Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenging a concept: Pulsed treatment regimen-No risk of PML?
    Warnke C; Hartung HP
    Mult Scler; 2019 Jul; 25(8):1076-1078. PubMed ID: 30964427
    [No Abstract]   [Full Text] [Related]  

  • 18. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    Heesen C; Kleiter I; Meuth SG; Krämer J; Kasper J; Köpke S; Gaissmaier W
    J Neurol Sci; 2017 May; 376():181-190. PubMed ID: 28431609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Washout period for immune-modifying drugs before natalizumab therapy.
    Ilanjian H; Shane R
    Am J Health Syst Pharm; 2008 Jan; 65(1):18-9. PubMed ID: 18159033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.